Single domain antibodies from llama effectively and specifically block T cell ecto‐ADP‐ribosyltransferase ART2.2 in vivo
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The purpose of our study was to develop a tool for blocking the function of a specific leukocyte ecto‐enzyme in vivo. ART2.2 is a toxin‐related ecto‐enzyme that transfers the ADP‐ribose moiety from NAD onto other cell surface proteins. ART2.2 induces T cell death by activating the cytolytic P2×7 purinoceptor via ADP‐ribosylation. Here, we report the generation of ART2.2‐blocking single domain antibodies from an immunized llama. The variable domain of heavy‐chain antibodies (VHH domain) represents the smallest known antigen‐binding unit generated by adaptive immune responses. Their long CDR3 endows VHH domains with the extraordinary capacity to extend into and block molecular clefts. Following intravenous injection, the ART2.2‐specific VHH domains effectively shut off the enzymatic and cytotoxic activities of ART2.2 in lymphatic organs. This blockade was highly specific (blocking ART2.2 but not the related enzymes ART1 or ART2.1), rapid (within 15 min after injection), and reversible (24 h after injection). Our findings constitute a proof of principle that opens up a new avenue for targeting leukocyte ecto‐enzymes in vivo and that can serve as a model also for developing new antidotes against ADP‐ribosylating toxins.—Koch‐Nolte, F., Reyelt, J., Schöβow, B., Schwarz, N., Scheuplein, F., Rothenburg, S., Haag, F., Alzogaray, V., Cauerhff, A., and Goldbaum, F. A. Single domain antibodies from llama effectively and specifically block T cell ecto‐ADP‐ribosyltransferase ART2.2 in vivo. FASEB J. 21, 3490–3498 (2007)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241 · cited 1×
“BLOCKING ART2.2 WITH SINGLE DOMAIN ANTIBODIES 3491 hinge classes of heavy-chain antibodies were purified from preimmune and immune sera of the ART2.2-immunized llama by consecutive affinity chromatography on protein A and protein G sepharose columns ( 15 ).”
Method
Cited by
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
A general protocol for the generation of Nanobodies for structural biology
Pardon, E., Laeremans, T., Triest, S., Rasmussen, S. G. F., Wohlkönig, A., Ruf, A., Muyldermans, S., Hol, W. G. J., Kobilka, B. K., & Steyaert, J. (2014) · Nature Protocols · doi:10.1038/nprot.2014.039 · Cited by 790
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“Daratumumab (anti-CD38), for example, was generated from immunized human Ig-transgenic mice, necitumumab (antiEGFR) was selected from a fully synthetic Fab display library (44).”
BackgroundInfluentialSingle domain antibodies: promising experimental and therapeutic tools in infection and immunity
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juarez, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., Scheuplein, F., et al. (2009) · Medical Microbiology and Immunology · doi:10.1007/s00430-009-0116-7 · Cited by 513
Self-citationThe P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in Models of Disease
Bartlett, R., Stokes, L., & Sluyter, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008003 · Cited by 393
A guide to: generation and design of nanobodies
Muyldermans, S. (2021) · The FEBS Journal · doi:10.1111/febs.15515 · Cited by 352
Muyldermans, S. (2021) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-021419-083831 · Cited by 338
Nanobodies and Their Potential Applications
Hassanzadeh-Ghassabeh, G., Devoogdt, N., De Pauw, P., Vincke, C., & Muyldermans, S. (2013) · Nanomedicine · doi:10.2217/nnm.13.86 · Cited by 328
Exploiting Nanobodies’ Singular Traits
Ingram, J. R., Schmidt, F. I., & Ploegh, H. L. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053327 · Cited by 254
T RM maintenance is regulated by tissue damage via P2RX7
Stark, R., Wesselink, T. H., Behr, F. M., Kragten, N. A. M., Arens, R., Koch-Nolte, F., van Gisbergen, K. P. J. M., & van Lier, R. A. W. (2018) · Science Immunology · doi:10.1126/sciimmunol.aau1022 · Cited by 141
Self-citationP2X7 on Mouse T Cells: One Channel, Many Functions
Rissiek, B., Haag, F., Boyer, O., Koch-Nolte, F., & Adriouch, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00204 · Cited by 116
“2antagonizing nanobody (clone s+ 16a) has been developed (56) and was shown to prevent ADP-ribosylation-related detrimental effects induced during ex vivo cell preparation when injected a few minutes before sacrificing the mice (Figure 2).”
BackgroundSelf-citationRissiek, B., Lukowiak, M., Raczkowski, F., Magnus, T., Mittrücker, H.-W., & Koch-Nolte, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01580 · Cited by 45
Self-citation
Metadata
- Authors
- Koch-Nolte, F., Reyelt, J., Schößow, B., Schwarz, N., Scheuplein, F., Rothenburg, S., Haag, F., Alzogaray, V., Cauerhff, A., & Goldbaum, F. A.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2007-06-15
- Volume
- 21
- Issue
- 13
- Pages
- 3490-3498
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2108162986
- Cited by
- 119
- References
- 1
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.